Paul J Martin
#146,998
Most Influential Person Now
Researcher
Paul J Martin's AcademicInfluence.com Rankings
Paul J Martinengineering Degrees
Engineering
#5779
World Rank
#7052
Historical Rank
Electrical Engineering
#1642
World Rank
#1740
Historical Rank

Paul J Martincomputer-science Degrees
Computer Science
#7452
World Rank
#7849
Historical Rank
Computational Linguistics
#1485
World Rank
#1501
Historical Rank
Machine Learning
#2747
World Rank
#2782
Historical Rank
Artificial Intelligence
#3041
World Rank
#3087
Historical Rank

Download Badge
Engineering Computer Science
Paul J Martin's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Paul J Martin Influential?
(Suggest an Edit or Addition)Paul J Martin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2005) (3030)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease (2015) (2244)
- Reduced mortality after allogeneic hematopoietic-cell transplantation. (2010) (1297)
- Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. (2002) (935)
- Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. (2003) (566)
- Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. (2011) (525)
- Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. (2003) (469)
- First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. (2012) (459)
- Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. (2006) (440)
- Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. (2003) (395)
- Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. (2002) (389)
- Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. (2005) (383)
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. (2009) (347)
- Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. (2014) (324)
- Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. (2004) (320)
- Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts (1985) (309)
- Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. (2010) (303)
- Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. (2006) (299)
- Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. (2015) (283)
- Duration of immunosuppressive treatment for chronic graft-versus-host disease. (2004) (272)
- Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. (2002) (269)
- The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. (2017) (267)
- Limits of HLA mismatching in unrelated hematopoietic cell transplantation. (2004) (265)
- Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. (2015) (264)
- Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. (2003) (259)
- Involvement of the B-lymphoid system in chronic myelogenous leukaemia (1980) (254)
- Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. (2002) (253)
- How we treat chronic graft-versus-host disease. (2015) (234)
- Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. (2003) (233)
- Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. (2005) (231)
- Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. (2009) (226)
- Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. (2007) (217)
- High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. (2003) (216)
- High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. (2002) (210)
- Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. (2008) (205)
- Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. (2011) (203)
- Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. (2003) (197)
- NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. (2015) (189)
- A Risk Score for Mortality after Allogeneic Hematopoietic Cell Transplantation (2006) (185)
- Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. (2013) (183)
- SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 (2001) (182)
- Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. (2017) (177)
- THE USE OF RADIOLABELED ANTI‐CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA (1992) (175)
- A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. (2015) (167)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. (2015) (164)
- Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. (2016) (161)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. (2006) (160)
- A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. (2002) (158)
- MHC Haplotype Matching for Unrelated Hematopoietic Cell Transplantation (2007) (154)
- Airflow Decline after Myeloablative Allogeneic Hematopoietic Cell Transplantation: The Role of Community Respiratory Viruses (2006) (151)
- Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. (2004) (150)
- The biological significance of HLA‐DP gene variation in haematopoietic cell transplantation (2001) (149)
- 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. (2006) (144)
- Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. (2009) (144)
- Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. (2003) (138)
- Allogeneic hematopoietic stem cell transplantation for myelofibrosis. (2003) (136)
- Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. (2016) (134)
- Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. (2002) (123)
- A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. (2005) (123)
- Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. (2009) (117)
- An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. (2006) (116)
- Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. (2006) (116)
- Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. (2007) (114)
- HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. (2012) (112)
- Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. (2009) (111)
- Biomarker Panel for Chronic Graft-Versus-Host Disease. (2016) (107)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. (2015) (107)
- Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. (2011) (106)
- Cardiovascular Hospitalizations and Mortality Among Recipients of Hematopoietic Stem Cell Transplantation (2011) (105)
- Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. (2012) (104)
- Hematopoietic stem cell transplants from unrelated donors (1997) (103)
- What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants ? (1990) (102)
- Graft‐versus‐host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long‐term follow‐up of a controlled trial (1989) (102)
- CD28-Specific Antibody Prevents Graft-Versus-Host Disease in Mice1 (2000) (101)
- Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts (2020) (101)
- Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. (2016) (100)
- Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. (2015) (100)
- Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long‐term follow‐up (2005) (99)
- Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. (2014) (97)
- Evaluation of published single nucleotide polymorphisms associated with acute GVHD. (2012) (94)
- Delivering care to long-term adult survivors of hematopoietic cell transplantation. (2012) (92)
- Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. (2013) (92)
- Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase (1998) (90)
- Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. (2002) (90)
- Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. (2012) (89)
- Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. (2014) (88)
- Treatment of chronic graft-versus-host disease: Past, present and future (2011) (88)
- Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation (2014) (87)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. (2015) (86)
- Monoclonal antibodies identifying a novel T-Cell antigen and Ia antigens of human lymphocytes (1980) (86)
- Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease (2009) (86)
- Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. (2014) (85)
- Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. (2006) (85)
- A survey of diagnosis, management, and grading of chronic GVHD. (2002) (85)
- Host T Cells Resist Graft-Versus-Host Disease Mediated by Donor Leukocyte Infusions1 (2000) (85)
- Validation of measurement scales in ocular graft-versus-host disease. (2012) (83)
- Monoclonal antibody 9.3 and anti‐CD11 antibodies define reciprocal subsets of lymphocytes (1985) (83)
- Late cardiovascular complications after hematopoietic cell transplantation. (2014) (82)
- Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. (2014) (82)
- Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. (2012) (80)
- Resilience, health, and quality of life among long‐term survivors of hematopoietic cell transplantation (2015) (79)
- Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. (2017) (78)
- Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. (2002) (78)
- Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. (2011) (77)
- A Phase 3 randomized study of Remestemcel-L versus placebo added to second line therapy in patients with steroid refractory acute graft versus host disease. (2020) (75)
- Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. (2013) (74)
- Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. (2017) (74)
- Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. (2005) (74)
- Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. (2014) (72)
- PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells (2017) (71)
- CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. (2004) (70)
- Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial (2015) (68)
- A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation (2015) (67)
- Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease (2009) (66)
- Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. (2016) (66)
- Disparity for a newly identified minor histocompatibility antigen, HA‐8, correlates with acute graft‐versus‐host disease after haematopoietic stem cell transplantation from an HLA‐identical sibling (2003) (66)
- Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. (2004) (65)
- Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. (2016) (64)
- A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial) (2003) (63)
- Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. (2002) (63)
- Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. (2014) (62)
- A novel soluble form of Tim-3 associated with severe graft-versus-host disease. (2013) (61)
- Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. (2002) (61)
- Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. (2009) (61)
- Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. (2019) (61)
- Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. (2011) (61)
- Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1. (2006) (60)
- Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. (2005) (60)
- HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. (2010) (59)
- Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. (2013) (58)
- Biology of chronic graft-versus-host disease: implications for a future therapeutic approach. (2008) (58)
- Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life. (2015) (58)
- TREATMENT OF ACUTE GRAFT‐VERSUS‐HOST DISEASE WITH A NONMITOGENIC ANTI‐CD3 MONOCLONAL ANTIBODY (1992) (58)
- A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. (2004) (56)
- Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. (2015) (56)
- Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. (2012) (54)
- Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. (2011) (54)
- The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice. (2005) (53)
- A PHASE I‐II STUDY EVALUATING THE MURINE ANTI‐IL-2 RECEPTOR ANTIBODY 2A3 FOR TREATMENT OF ACUTE GRAFT‐VERSUS-HOST DISEASE (1990) (52)
- Signal transduction by HLA class II antigens expressed on activated T cells (1991) (52)
- Secondary treatment of acute graft-versus-host disease: a critical review. (2012) (52)
- Risk factors for depression and fatigue among survivors of hematopoietic cell transplantation (2016) (51)
- Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. (2009) (51)
- A guide to research partnerships for pragmatic clinical trials (2014) (50)
- Assessment of Joint and Fascia Manifestations in Chronic Graft‐Versus‐Host Disease (2014) (49)
- Clinical benefit of response in chronic graft-versus-host disease. (2012) (47)
- Homotypic aggregation of human cell lines by HLA class II‐, class Ia‐ and HLA‐G‐specific monoclonal antibodies (1991) (47)
- Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. (2008) (47)
- Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. (2017) (47)
- Effects of race on survival after stem cell transplantation. (2005) (47)
- Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. (2008) (46)
- Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation (2010) (46)
- Diagnosis and clinical management of chronic graft-versus-host disease (2004) (44)
- Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. (2010) (43)
- An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. (2017) (43)
- Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. (2011) (42)
- Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐ specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation (2015) (42)
- Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease (2017) (41)
- An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation (2018) (41)
- Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation. (2013) (40)
- Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. (2017) (40)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report (2021) (40)
- Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. (2006) (39)
- Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. (2010) (39)
- Involvement of Donor T-Cell Cytotoxic Effector Mechanisms in Preventing Allogeneic Marrow Graft Rejection (1998) (38)
- CD28 Signal Enhances Apoptosis of CD8 T Cells After Strong TCR Ligation 1 (2003) (38)
- Current challenges in chronic graft-versus-host disease. (2010) (38)
- Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors. (2014) (37)
- Prognostic relevance of ‘early‐onset’ graft‐versus‐host disease following non‐myeloablative haematopoietic cell transplantation (2005) (37)
- Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. (2007) (37)
- Anti-CD3ε F(ab′)2 Prevents Graft-Versus-Host Disease by Selectively Depleting Donor T Cells Activated by Recipient Alloantigens1 (2001) (37)
- Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation (2006) (37)
- A phase I / II trial of iodine-131 – tositumomab ( anti-CD 20 ) , etoposide , cyclophosphamide , and autologous stem cell transplantation for relapsed B-cell lymphomas (2000) (36)
- Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. (2015) (36)
- Lung function and long-term complications after allogeneic hematopoietic cell transplant. (2010) (35)
- Langerhans Cell Homeostasis and Turnover After Nonmyeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation (2014) (35)
- Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium. (2013) (35)
- Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation (2009) (35)
- Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. (2016) (34)
- A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. (2011) (34)
- IL10 and IL10 Receptor Gene Variation and Outcomes After Unrelated and Related Hematopoietic Cell Transplantation (2009) (34)
- Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. (2005) (33)
- How I treat steroid-refractory acute graft-versus-host disease. (2020) (33)
- Prognostic utility of routine chimerism testing at 2 to 6 months after allogeneic hematopoietic cell transplantation. (2009) (33)
- Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease. (2015) (32)
- ORAL BECLOMETHASONE DIPROPIONATE FOR TREATMENT OF HUMAN INTESTINAL GRAFT‐VERSUS-HOST DISEASE (1995) (32)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. (2021) (32)
- Simultaneous genotyping of single nucleotide polymorphisms in the IL-1 gene complex by multiplex polymerase chain reaction-restriction fragment length polymorphism. (2002) (31)
- Visual Acuity and Anterior Segment Findings in Chronic Graft-Versus-Host Disease (2011) (31)
- Spiritual or religious struggle in hematopoietic cell transplant survivors (2017) (31)
- Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease (2014) (31)
- Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease. (2017) (29)
- Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. (2005) (28)
- Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain (2004) (28)
- Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease. (2006) (28)
- Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease (2015) (28)
- Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors. (2016) (28)
- Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. (2011) (27)
- Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. (2013) (27)
- Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. (2015) (27)
- Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. (2012) (27)
- Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. (2016) (26)
- Chronic graft-versus-host disease: how can we release Prometheus? (2008) (26)
- Multivariate Detection of Gene‐Gene Interactions (2012) (25)
- Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism (1996) (25)
- A new human T-cell differentiation antigen: Unexpected expression on chronic lymphocytic leukemia cells (2005) (25)
- Study design and endpoints in graft-versus-host disease. (2008) (25)
- Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. (2017) (24)
- Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes (2008) (24)
- Medical and psychosocial issues in transplant survivors (2007) (24)
- Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease (2003) (23)
- Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial (1997) (23)
- Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80 (2018) (23)
- Ten HLA-DR 4 alleles defined by sequence polymorphisms within the DRB 1 first domain (23)
- Responsibility for costs associated with clinical trials. (2014) (22)
- Simultaneous genotyping of single nucleotide polymorphisms in the IL-6, IL-10, TNFα and TNFβ genes (2002) (22)
- Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease (2014) (22)
- Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. (2008) (22)
- 131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). (2005) (22)
- Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD (2014) (21)
- Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. (2020) (21)
- Success of allogeneic marrow transplantation for children with severe aplastic anaemia (2012) (21)
- A combined biomarker and clinical panel for chronic graft versus host disease diagnosis (2016) (20)
- Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease. (2011) (20)
- Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. (2018) (19)
- Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose (2012) (19)
- Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation (2018) (19)
- Overview of Hematopoietic Cell Transplantation Immunology (2009) (17)
- Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease. (2005) (17)
- Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation (2017) (17)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. (2021) (17)
- Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia. (2017) (17)
- Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. (2017) (17)
- A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. (2011) (17)
- Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease (2022) (16)
- Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. (2009) (16)
- Application of CIBMTR risk score to NIH chronic GVHD at individual centers. (2014) (16)
- Thalidomide for treatment of patients with chronic graft-versus-host disease (2000) (16)
- A ricin A chain-containing immunotoxin that kills human T lymphocytes in vitro (1985) (16)
- Genetic risk factors for sclerotic graft-versus-host disease. (2014) (16)
- Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease. (2012) (15)
- Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. (2015) (15)
- Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades (2020) (15)
- A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT) (2016) (15)
- Improving hematopoietic cell transplant outcomes in a new era of genomic research. (2009) (15)
- National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. (2017) (15)
- Confounding Factors Affecting the National Institutes of Health (NIH) Chronic Graft-Versus-Host Disease Organ-Specific Score and Global Severity (2016) (15)
- Disability Related to Chronic Graft-Versus-Host Disease. (2020) (14)
- Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease (2017) (14)
- Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host-disease-associated autoimmunity. (2020) (14)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. (2021) (14)
- PD-L 1 interacts with CD 80 to regulate graft-versus-leukemia activity of donor CD 8 + T cells (2018) (13)
- Expanding Assessments of Translational Research Programs (2014) (13)
- Preincubation of donor bone marrow cells with a combination of murine monoclonal anti-T-cell antibodies without complement does not prevent graft-versus-host disease after allogeneic marrow transplantation (2004) (13)
- Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients. (2014) (13)
- Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation. (2009) (13)
- Evolution of epitopes on human and nonhuman primate lymphocyte cell surface antigens (2004) (13)
- Allogeneic hematopoietic cell transplantation after conditioning with 131 I – anti-CD 45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome (2009) (12)
- Keratinocyte dysplasia in hematopoietic stem cell transplantation recipients in the day-28-to-84 posttransplantation period. (2012) (12)
- Engagement with INSPIRE, an Online Program for Hematopoietic Cell Transplantation Survivors. (2018) (12)
- Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD). (2009) (12)
- CD34 Cell Dose and Chronic Graft-versus-Host Disease after Human Leukocyte Antigen-Matched Sibling Hematopoietic Stem Cell Transplantation (2004) (12)
- Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. (2019) (12)
- CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. (2017) (12)
- Winning the battle of graft versus host (2000) (12)
- Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. (2019) (11)
- Long-Term Comparison of Immunosuppressive Therapy with Antithymocyte Globulin to Bone Marrow Transplantation in Aplastic Anemia (1990) (11)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. (2021) (10)
- Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation. (2004) (10)
- Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. (2019) (10)
- The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. (2021) (10)
- 131 I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission. (2004) (10)
- Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. (2020) (10)
- A proposed objective way to assess results of randomized prospective clinical trials with acute graft‐versus‐host disease as an outcome of interest (2001) (10)
- Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI). (2009) (10)
- Unusual distribution of Ia-like antigens on canine lymphocytes (2004) (10)
- PRELIMINARY RESULTS OF A PHASE II TRIAL OF IODINE-131-LABELED ANTI-CD20 (B1) ANTIBODY THERAPY WITH BONE MARROW RESCUE FOR PATIENTS WITH RELAPSED B CELL LYMPHOMAS (1994) (10)
- Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. (2020) (10)
- Allogeneic marrow transplantation (1993) (10)
- Pathogenic neutrophils in acute GVHD. (2018) (9)
- IL-22-dependent dysbiosis and mononuclear phagocyte depletion contribute to steroid-resistant gut graft-versus-host disease in mice (2021) (9)
- Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft Versus Host Disease. (2021) (9)
- Influence of Metabolic Traits and Lifestyle Factors on Cardiovascular Disease After Hematopoietic Cell Transplantation (2012) (8)
- IL 10 AND IL 10 RECEPTOR GENE VARIATION AND OUTCOMES AFTER UNRELATED AND RELATED HEMATOPOIETIC CELL TRANSPLANTATION (2009) (8)
- Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation. (2002) (8)
- Influence of Metabolic Traits and Lifestyle Factors on Cardiovascular Disease After Hematopoietic Cell Transplantation (2012) (8)
- Role of CD 28 in Acute Graft-Versus-Host Disease (1998) (8)
- Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation. (2020) (8)
- Unique sequences for two HLA-DRB1 genes expressed on distinct DRw6 haplotypes (2004) (7)
- Biology and management of chronic graft-versus-host disease. (2009) (7)
- Chemokine expression in Th 1 cell-induced lung injury : prominence of IFN-g-inducible chemokines (2000) (7)
- Transplantation and aging. (2006) (7)
- SYNERGISM BETWEEN IL-10 GENOTYPE OF PATIENT AND IL-10 RECEPTOR-β GENOTYPE OF DONOR (2005) (7)
- A Multi-Center, Randomized, Double Blind, Phase III Clinical Trial Comparing Steroids/Placebo Vs. Steroids/Mycophenolate Mofetil As Initial Therapy for Acute Graft-Versus-Host Disease. Blood and Marrow Transplant Clinical Trials Network Study 0802 (2013) (7)
- Phenotyping human leukemic T-Cell lines: Enzyme markers; surface antigens, and cytogenetics (2004) (7)
- I-Anti-CD 45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome (1999) (7)
- Endpoints for Clinical Trials Testing Treatment of Acute Graft- versus-host Disease: A Consensus Document (2010) (7)
- The impact of members of the Society of University Surgeons on the scholarship of American surgery. (2016) (6)
- High-Dose Radioimmunotherapy of B Cell Lymphomas1 (1989) (6)
- Chronic Graft versus Host Disease: Interdisciplinary Management: Front Line Treatment of Chronic Graft versus Host Disease (2009) (6)
- Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial (2016) (6)
- Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. (2021) (6)
- Impact of clinical fellowships on academic productivity in departments of surgery. (2016) (6)
- IgG anti-tetanus toxoid antibody synthesis by human bone marrow. I. Two distinct populations of marrow B cells and functional differences between marrow and peripheral blood B cells (1990) (6)
- HLA and marrow transplants from unrelated donors (1994) (6)
- The positive association of Association for Academic Surgery membership with academic productivity. (2016) (6)
- Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (5)
- Genetic Variants Associated with Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation. (2021) (5)
- Association of Pre-Transplant Comorbidities with Long-Term Quality of Life (QOL) Among Survivors After Allogeneic Hematopoietic Cell Transplantation (HCT) (2013) (5)
- Mantle Zone and Germinal Center B cells Respond to Different Activation Signals (1985) (5)
- Choosing between GVHD and delayed engraftment (2009) (5)
- Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine. (2010) (4)
- Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation: Plasma MMP-9 in BOS. (2021) (4)
- The Chronic Graft-vs.-Host Disease Failure-Free Survival (cGVHD-FFS) index. (2019) (4)
- Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial (2013) (4)
- Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK Pathway (2022) (4)
- Seattle Symposium on Cancer Research Outcomes: Commentary on the Papers by Donaldson and Moinpour and by Osoba (2002) (4)
- CIK: a path to GVL without GVHD? (2011) (4)
- Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival (2021) (4)
- Incidence, Risk Factors, and Prognosis of Late Immune-Mediated Disorders after Allogeneic Hematopoietic Cell Transplantation (HCT) (2015) (4)
- Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens. (2006) (4)
- Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation (2010) (4)
- Use of Flow Microfluorometry in Bone Marrow Transplantation a (1984) (4)
- Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes (2011) (4)
- Effect of disparity in the newly identified minor histocompatibility antigen SKH13 on the development of graft-versus-host disease after marrow transplantation from an HLA-identical sibling (2000) (4)
- A Multicenter Phase I/II Study of Relapse Prophylaxis with Nilotinib after Hematopoietic Cell Transplantation (HCT) for High-Risk Philadelphia Chromosome-Positive (Ph+) Leukemias (2015) (3)
- Reversing CD8+ T-cell exhaustion with DLI. (2014) (3)
- Risk Factors for Graft Rejection of Marrow Transplants From HLA Haploidentical Donors (1989) (3)
- A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation (2021) (3)
- Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. (2022) (3)
- Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes (2011) (3)
- Association of plasma CD 163 concentration with de novo-onset chronic graft-versus-host disease (2017) (3)
- Sitagliptin to Prevent Acute Graft-versus-Host Disease. (2021) (3)
- Studies of T Cell Proliferation Induced by Monoclonal Antibodies of the Second International Workshop (1986) (3)
- RADIOLABELED ANTIBODY THERAPY OF RELAPSED B CELL LYMPHOMAS (1993) (2)
- Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans (2021) (2)
- A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation (2015) (2)
- Outcomes among Patients with Recurrent High-Risk Hematologic Malignancy after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Cell Transplantation. (2006) (2)
- Chapter 2 – Monoclonal Antilymphocyte Antibodies: Probes for the Study of the Regulation of Hematopoiesis and Potential Clinical Applications1 (1983) (2)
- Outcome of Hematopoietic Cell Transplant from HLA-Matched Siblings Compared to a Volunteer Unrelated Donors Matched for HLA-A, B, C, DRB1, and DQB1 Alleles. (2007) (2)
- Effect of HLA-DRB1 and DQB1 allele disparity on the development of acute graft versus host disease following unrelated donor marrow transplantation (1994) (2)
- Confounding Factors Affecting the National Institutes of Health (NIH) Chronic GVHD Organ-Specific Score and Global Severity (2014) (2)
- Bortezomib for prevention of acute graft-versus-host disease: a conclusion reached (2018) (2)
- Safety and Potential Efficacy of Low Dose Methotrexate for Treatment of Chronic Graft-Versus-Host Disease. (2004) (2)
- Infections Post Transplant Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation (2003) (2)
- Impact of molecular histocompatibility typing on outcome of unrelated donor hematopoietic cell transplantation (2002) (2)
- Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation (2015) (2)
- Marrow Transplants from Unrelated Donors for the Treatment of High-Risk Acute Leukemia (1998) (2)
- Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes (2011) (2)
- Evaluation of Published Single-Nucleotide Polymorphisms (SNPs) Associated with Cytomegalovirus Infection and Disease after Hematopoietic Cell Transplantation in a Large Caucasian Cohort (2014) (2)
- Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. (2019) (2)
- Immune Rejection: The Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation (from Mice to Humans) (2013) (2)
- ANG2/VEGF in steroid-refractory GVHD. (2011) (2)
- Comparison of Tacrolimus Versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: A CIBMTR Analysis (2014) (1)
- Allogeneic and Syngeneic Marrow Transplantation for Aplastic Anemia: Overview of Seattle (1988) (1)
- Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation. (2009) (1)
- Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium (2010) (1)
- Survival without Progressive Impairment As a Novel Endpoint in Chronic Graft-Versus-Host Disease (2015) (1)
- Failure-Free Survival After Initial Systemic Treatment Of Chronic GVHD (2013) (1)
- Statins Synergize With Cyclosporine in Inhibiting Mitochondrial Function in Activated T Cells (2011) (1)
- Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (1)
- Identification of Modifiable Factors Associated with Lower Adherence to Preventive Care Practices In HCT Survivors. (2010) (1)
- Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin (2021) (1)
- MEKing it easier to prevent GVHD. (2013) (1)
- Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (2016) (1)
- 47: Prospective Neurocognitive Function and Risk Factors at 5 Years After Allogeneic Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies, Compared with Controls at 5 Years (2008) (1)
- Efficacy of Remestemcel-L Treatment in Steroid Refractory Acute Graft-Versus-Host Disease in Children: An Aggregate Analysis (2020) (1)
- Association of IL-10 and IL-10 Receptor Gene Polymorphisms and Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation. (2004) (1)
- Retransplantation of marrow and hematopoietic stem cells from normal donors (1997) (1)
- Rare Variant Genetic Association Study for Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Via Whole Exome Sequencing (2021) (1)
- A Biomarker Panel for Chronic Graft-Versus-Host Disease (2015) (1)
- Frequency and Intensity of Antibody Responses to Antigens Encoded by KDM5D (SMCY) and Other H-Y Genes After Allogeneic Hematopoietic Cell Transplantation, (2011) (1)
- Correlation Between Severity of Oral Mucositis and Both Overall and Gut Acute GvHD After High Intensity Conditioning Hematopoietic Stem Cell Transplantation. (2012) (1)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report Transplantation and Cellular Therapy (2021) (1)
- HISTOPATHOLOGIC DIAGNOSIS OF CHRONIC GRAFT VERSUS HOST DISEASE 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: II. Pathology Working Group Report (2006) (1)
- Change in NIH Skin Score 0–3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium (2011) (1)
- Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium (2011) (1)
- Clinical Research 1016 Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease (2007) (1)
- Hardy's "Small" Discovery Remembered. (2008) (1)
- Regional Analysis of Candidate Genes Associated With Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (2011) (1)
- Trafficking between clonally related peripheral T helper cells and tissue-resident T helper cells in chronic GVHD. (2022) (1)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report Transplantation and Cellular Therapy (2021) (1)
- Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease (2022) (1)
- 20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis (2021) (1)
- Graft-Versus-Host Disease in Mice CD28-Specific Antibody Prevents (2017) (1)
- Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study (2014) (1)
- Clinical manifestation of chronic graft-versus-host disease (cGVHD) after transplantation of peripheral blood stem cell (PBSC) compared to bone MARROW (BM) (2000) (1)
- 434 Association of skin response in erythema and sclerosis with survival in chronic graft-versus-host disease (2020) (1)
- The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation (2012) (1)
- Response to Krejci and Mayer (2010) (1)
- Durable Discontinuation of Immunosuppressive Therapy (IST): Clinical Results from the Chronic GvHD Consortium (2021) (1)
- Cell biology comes to the bedside (2007) (1)
- ncreasingly Frequent Diagnosis of Acute astrointestinal Graft-versus-Host Disease after llogeneic Hematopoietic Cell Transplantation (2004) (1)
- Selected reviews from the 2014 BMT Tandem meetings [corrected]. (2014) (1)
- Cyclosporine (CSP) or CSP plus methylprednisolone for graft-versus-host- disease prophylaxis in patients with high-risk lymphohemopoietic malignancies (2000) (1)
- HISTOPATHOLOGIC DIAGNOSIS OF CHRONIC GRAFT VERSUS HOST DISEASE: NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: II. The 2014 Pathology Working Group Report (2015) (1)
- Chapter 18. Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation (2007) (1)
- Risk Factors for Depression and Fatigue Among Hematopoietic Cell Transplant (HCT) Recipients (2015) (1)
- Neutralizing IL-2 Early after HCT Specifically Prevents Expansion of Donor GM-CSF-Producing CD4+ T Cells That Initiate Acute Gut Gvhd (2018) (0)
- A Phase II Study of Bandage Contact Lenses for Ocular Graft-Versus-Host Disease (2015) (0)
- Changes in CD4+ T Cells and Regulatory T Cells (Treg) in Chronic Graft-Versus-Host Disease (cGVHD) (2011) (0)
- chronic GVHD Evaluation of NIH consensus criteria for classification of late acute and (2009) (0)
- Lithium attenuates graft-versus-host disease via effects on the intestinal stem cell niche. (2022) (0)
- Treatment of Chronic Graft-versus-Host Disease - Progress to Date and Challenges Ahead (2019) (0)
- Stat3-/- Alloreactive Donor T Cells Reduce FAO but Increase Leakage of ROS in Response to PD-1 Signaling Triggered By Host-Tissue PD-L1, Leading to Prevention of Gvhd While Preserving GVL Effect (2019) (0)
- Targeting Intestinal Epithelial Ceacam1 Expands Peripheral Tregs and Prevents Steroid-Refractory Acute Gut Graft-Versus-Host Disease (2022) (0)
- Immunogenetics of allogeneic hematopoietic transplantation (1996) (0)
- Physician-Reported CR+PR at 6 Months Predicts Subsequent Survival in Patients with Chronic GVHD (2015) (0)
- Elimiation of PDGF-B from only the circulating cells of APOE −/− mice significantly impacts atherosclerotic lesion formation (2000) (0)
- Comorbidity Indexes and Allogeneic Stem Cell Transplantation (SCT). (2007) (0)
- regimens after hematopoietic cell transplantation with myeloablative conditioning An acute graft-versus-host disease activity index to predict survival (2010) (0)
- ncillary Therapy and Supportive Care of Chronic raft-versus-Host Disease : National Institutes of ealth Consensus Development Project on Criteria or Clinical Trials in Chronic Graft-versus-Host isease : V . Ancillary Therapy and Supportive Care orking Group Report (2006) (0)
- Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival. (2023) (0)
- Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease (2017) (0)
- Pulmonary symptoms measured by the NIH Lung score predict overall survival, non-relapse mortality and patient-reported outcomes in chronic GVHD (2014) (0)
- Gene Expression in CD4+ T Cells of Patients With and Without Chronic Graft-Vs-Host Disease (cGVHD) (2011) (0)
- Allogeneic Marrow Graft Rejection Involvement of Donor T-Cell Cytotoxic Effector Mechanisms in Preventing (1998) (0)
- Elements compositional detection system and method (2010) (0)
- Chronic Graft versus Host Disease: Interdisciplinary Management: Design of Clinical Trials Testing Treatment for Chronic Graft versus Host Disease (2009) (0)
- Comparison between short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease (2011) (0)
- Prognostic Factors and Outcomes of Severe Gastrointestinal Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation (2008) (0)
- A Retrospective Comparison of Tacrolimus Vs. Cyclosporine for Immunosuppression After Allogeneic Hematopoietic Cell Transplantation with G-CSF-Mobilized Blood Cells (2010) (0)
- How I Treat How we treat chronic graft-versus-host disease (2015) (0)
- Myeloablative Transplant (HCT) (2012) (0)
- HLA Typing in Support of Hematopoietic Cell Transplantation from Unrelated Donors (2013) (0)
- Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation (2015) (0)
- FAM treatment for new onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation (2016) (0)
- Host Tissue PD-L1 Separates GVL Effect from Gvhd after Temporary Depletion of Donor CD4 + T Cells Early after HCT (2015) (0)
- Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (2014) (0)
- Prediction of outcomes after second-line treatment for acute graft-versus-host disease (2022) (0)
- -inducible chemokines γ prominence of IFN- Chemokine expression in Th1 cell-induced lung injury: (2016) (0)
- Pulmonary Symptoms Measured by the NIH Lung Score Predict Overall Survival and Non-Relapse Mortality in Chronic GVHD (2013) (0)
- Tissue-Resident PSGL1loCD4+ T Cells Interact with B Cells Via PD-1 and PD-L2 in Gvhd Target Tissues to Augment Autoimmune-like Chronic Gvhd (2019) (0)
- Tc17 cells cause gut graft-versus-host disease through induction of dysbiosis and depletion of CX3CR1hi phagocytes (2020) (0)
- Seattle Symposium on Cancer Research Outcomes (2002) (0)
- Clinical Marrow Transplantation (1987) (0)
- hematopoietic stem cell transplantation Graft-versus-host disease after nonmyeloablative versus conventional (2014) (0)
- Comorbidity Burden in Patients with Chronic Graft Versus Host Disease (2014) (0)
- National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Research Methodology and Study Design (2016) (0)
- Obligation for transparency regarding treating physician credentials at academic health centres (2018) (0)
- Association of Graft-Versus-Host Disease and Immunosuppressive Treatment with Risks of Recurrent Malignancy and Mortality After Allogeneic Hematopoietic Cell Transplantation (2010) (0)
- Association Between AGT SNPs, Plasma AGT Levels, and Risk for IPS After Allogeneic HCT (2013) (0)
- disease: a multicenter study Performance of a new clinical grading system for chronic graft-versus-host (2013) (0)
- Expansion of Th/Tc17 T Cells and Loss of CX3CR1+ Macrophages Play a Critical Role in the Pathogenesis of Steroid-Refractory Acute Intestinal Gvhd (2019) (0)
- B itfalls in the Design of Clinical Trials for Prevention r Treatment of Acute Graft-versus-Host Disease (2006) (0)
- Genetic variants associated with inflammatory bowel disease and gut graft-versus-host disease (2021) (0)
- allogeneic hematopoietic stem cells Conditioning with fludarabine and targeted busulfan for transplantation of (2013) (0)
- Tissue Parenchymal Cell Expression of B7-H1 Inhibits Infiltrating T Cell Expansion and Prevents Persistence of Graft-Versus-Host Disease (2011) (0)
- Myelodysplastic Syndrome : The Transplanter ’ s Quandaries (2008) (0)
- SPECIFIC IgG ANTI-TETANUS TOXOID ANTIBODY SYNTHESIS BY HUMAN BOA MARROW MONONUCLEAR CELLS (1987) (0)
- Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Followed by Bortezomib Maintenance Therapy for High Risk Multiple Myeloma (2017) (0)
- Laboratory Correlates of Immune Reconstitution At 1-Year Following Related, Unrelated, and Umbilical Cord Blood Hematopoietic Stem Cell Transplantation: Correlation with Survival (2013) (0)
- Association of Comorbidity Scoring with Outcome in Patients with Chronic Graft Versus Host Disease (2013) (0)
- A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality (2014) (0)
- Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease. (2023) (0)
- Predictors of acute GVHD treatment outcomes 1 PREDICTIVE VALUE OF CLINICAL FINDINGS AND PLASMA BIOMARKERS AFTER 14 DAYS OF PREDNISONE TREATMENT FOR ACUTE GRAFT-VERSUS-HOST DISEASE (2017) (0)
- Analysis of Pulmonary Function Change Associated with Sclerotic Chronic Graft Versus Host Disease (ScGVHD) (2017) (0)
- Initial Systemic Therapy of Chronic Graft Vs. Host Disease: Analysis of Practice Variation and Failure-Free Survival (2021) (0)
- Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. (2022) (0)
- genotype of donor β synergism between IL-10 genotype of patient and IL-10 receptor graft-versus-host disease following hematopoietic cell transplantation: Genetic variation in the IL-10 pathway modulates severity of acute (2013) (0)
- Risk Factors for Late Cardiovascular Morbidity and Mortality After Hematopoietic Cell Transplantation (2011) (0)
- Graft-Versus-Host Disease: A Prospective, Randomized Trial Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of (2011) (0)
- Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium (2013) (0)
- Chronic Cutaneous GVHD Does Not Correlate with Frequency and FoxP3 Gene Expression of Regulatory T Cells. (2005) (0)
- Educating Radiologists for Self-governance. (2018) (0)
- Change of Treatment for Control of Chronic Graft-Versus-Host Disease (cGVHD) as a Time-Dependent Covariate for Nonrelapse Mortality and Survival. (2007) (0)
- Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation (2022) (0)
- Frequent Eczematous Dermatitis in Unrelated Cord Blood Hematopoietic Cell Transplant Recipients Compared With Other Donor Types Transplantation and Cellular Therapy (2021) (0)
- Risk Factors for Musculoskeletal Symptoms in 5-20 Year Survivors Who Received Myeloablative Hematopoietic Cell Transplant (HCT) (2014) (0)
- Immunologic regulation of allogeneic marrow engraftment (1996) (0)
- High Dose Radiolabeled Antibody Therapy of Lymphoma 1 (2006) (0)
- A Pilot Study Evaluating the Safety and Efficacy of Imatinib Given Early after Transplant for High-Risk Philadelphia Chromosome-Postive Leukemias. (2005) (0)
- Activation of Alveolar Macrophages Mononuclear Cell Inflammation and Cells Is Characterized by Host-Derived Lung Injury Induced by Alloreactive Th 1 (1998) (0)
- Stat3 Regulates Alloreactive T Cell Susceptibility Towards PD-L1-Mediated Tolerance Signaling, Gvhd and GVL Activity (2018) (0)
- TCR-MHC-peptide(s): in vivo veritas. (2011) (0)
- Incidence, Risk Factors and Outcomes of Sclerotic Chronic Graft-Versus-Host Disease (GVHD) Phenotype After Allogeneic Hematopoietic Cell Transplantation (2011) (0)
- Neutralization of IL-2 prevents acute GVHD while preserving GVL activity via regulating PD-L1/PD-1 signaling (2019) (0)
- S1P/S1PR1 Signalis Required for Optimal T-Cell Pathogenicity to Induce Gvhd By RegulatingDrp1/mTOR Axis (2021) (0)
- Two monoclonal murine antibodies that detect the human T cell E-rosette receptor: A comparative analysis (1982) (0)
- Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity (2023) (0)
- Progress in chronic graft-versus-host disease (2011) (0)
- Graft-Versus-Host Reaction T Cells in the + Antigen-Specific CD 8 Visualization , Fate , and Pathogenicity of Anasetti (1999) (0)
- Antithymocyte Globulin Aplastic Anemia Conditioned by Cyclophosphamide Combined With Long-Term Follow-Up of Allogeneic Marrow Transplants in Patients With (2011) (0)
- Cytomegalovirus breakthrough and resistance during letermovir prophylaxis (2023) (0)
- Utility of Grip Strength and 2 Minute Walk Test in Chronic GVHD Assessment: An Analysis From the Chronic GVHD Consortium (2013) (0)
- Predominant Pulmonary Vasculitis CD 45 Induce Graft-Versus-Host Disease with T Cells Specific for a Polymorphic Segment of Kusunoki (1998) (0)
- Allogeneic hematopoietic stem cell transplantation for myelofibrosis (2003) (0)
- Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium (2010) (0)
- TRANSPLANTATION Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease (2013) (0)
- Spiritual/religious struggle in hematopoietic cell transplant survivors. (2013) (0)
- Characterization of Chronic Graft-Versus-Host Disease and Duration of Immunosuppression After Cord Blood Transplantation, (2011) (0)
- Immune Correlates from a Prospective Trial Suggest Leukotriene Signaling and Alternative Macrophage Activation in Clinical Bronchiolitis Obliterans Syndrome (2021) (0)
- Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium (2012) (0)
- Late Cardiovascular Morbidity Following Pediatric Allogeneic Hematopoietic Cell Transplantation (2016) (0)
- Response Endpoints for Acute Graft-Versus-Host Disease Treatment Trials (2013) (0)
- Pretreatment with Anti-CD3 Monoclonal Antibody Depletes Recipient CCR7+ Dendritic Cells and Prevents Graft-Versus-Host Disease While Preserving GVL Effects, (2011) (0)
- Analysis of CD4 Gene Expression in Hematopoietic Cell Transplant (HCT) Tolerant Patients (141.20) (2009) (0)
- Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response (2011) (0)
- Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic GVHD (2019) (0)
- Infusions Disease Mediated by Donor Leukocyte Host T Cells Resist Graft-Versus-Host (2000) (0)
- New Strategies for Fungal Infections after Hematopoietic Cell Transplantation : Prevention or Preemption ? (2007) (0)
- Feasibility of home spirometry in patients with chronic graft-versus-host disease: a prospective observational study (2020) (0)
- Engraftment, Graft Rejection, and Graft Failure (2019) (0)
- Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD) (2022) (0)
- Indirect Effects of Cytomegalovirus Infection After Hematopoietic Cell Transplantation in the Preemptive Therapy Era (2015) (0)
- Persistence of Graft-Versus-Host Disease T Cells and + Infiltrating Donor CD 8 Parenchymal Cells Leads to Expansion of Loss of B 7-H 1 Expression by Recipient (2011) (0)
- Pathway-driven rare germline variants associated with transplant-associated thrombotic microangiopathy (TA-TMA). (2023) (0)
- Chromosome-Positive Acute Lymphoblastic Leukemia Marrow Transplants From Unrelated Donors for Treatment of Philadelphia (2011) (0)
- hematopoietic cell transplantation Risk factors for lymphoproliferative disorders after allogeneic (2013) (0)
- Association of Socioeconomic Status (SES) with Chronic Graft-Versus-Host Disease (cGVHD) Outcomes (2017) (0)
- Classic Papers and Current Comments Highlights of Leukemia Research (2002) (0)
- bone marrow transplantation Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic (2011) (0)
- Frequent Eczematous Dermatitis in Unrelated Cord Blood Hematopoietic Cell Transplant Recipients Compared to Other Donor Types. (2021) (0)
- Prospective Phase Ii Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bos Pathogenesis (2021) (0)
- prednisone does not compromise patient outcomes Initial therapy of acute graft-versus-host disease with low-dose (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Paul J Martin?
Paul J Martin is affiliated with the following schools: